All In Biotech

Drug Trial Radar · NCT07412613

Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer

A Randomized, Open-label, Controlled, Multicenter Phase 3 Clinical Trial of AK104 for Neoadjuvant/Adjuvant Treatment of Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer

Last checked: Nov 20, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 386 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

386

Planned (sponsor's estimate)

Start

Apr 15, 2026

Primary completion

Jun 15, 2030

Study completion Mar 15, 2031

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Feb 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, open-label, controlled, multicenter phase 3 study. All patients are resectable microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer. The purpose of this study is to evaluate the efficacy and safety of neoadjuvant/adjuvant treatment of AK104 (Cadonilimab) versus adjuvant chemotherapy in patients with resectable MSI-H/dMMR colon cancer.

Conditions

  • Resectable Colon Cancer
  • MSI-H/dMMR Colorectal Cancer

Interventions

  • Cadonilimab (AK104)Drug

    Anti-PD-1/CTLA-4 tetrameric bispecific antibody

  • OxaliplatinDrug

    Intravenous

  • CapecitabineDrug

    Oral

  • 5- FluorouracilDrug

    Intravenous

  • Calcium FolinateDrug

    Intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathologic Complete Response (pCR) rate as assessed by investigatorTime frame: 1 month after surgery
  2. Event Free Survival (EFS)Time frame: Up to approximately 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.